Immunogenicity

Vir Biotechnology Announces Initiation of Phase 1 Clinical Trial to Evaluate a Novel Vaccine Platform

Retrieved on: 
Wednesday, January 6, 2021
Health sciences, Medical specialties, Health, Vaccination, Clinical research, Clinical trial, Design of experiments, Pharmaceutical industry, Vaccine, Immunogenicity

This trial is being conducted in collaboration with Oregon Health & Science Universitys (OHSU) Vaccine and Gene Therapy Institutewith support from the Bill & Melinda Gates Foundation.

Key Points: 
  • This trial is being conducted in collaboration with Oregon Health & Science Universitys (OHSU) Vaccine and Gene Therapy Institutewith support from the Bill & Melinda Gates Foundation.
  • The randomized, placebo-controlled, Phase 1 clinical trial is evaluating the safety and immunogenicity (ability to induce an immune response) of VIR-1111.
  • Along with the many OHSU investigators who worked on this project over the years, we are very excited that this new vaccine platform is being evaluated in a clinical trial, Drs.
  • Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases.

ImmunityBio’s hAd5 T-Cell COVID-19 Vaccine Candidate Shows Complete Protection of Airways in Non-Human Primates

Retrieved on: 
Friday, December 11, 2020
Health, Infectious diseases, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Medical specialties, Medicine, Health sciences, Vaccines, Medical research, Vaccination, Virology, Vaccine, COVID-19 vaccine, Immunogenicity, Adenoviridae, Coronavirus disease, ImmunityBio and NantKwest Joint Collaboration Agreement, ImmunityBio, NantKwest

By protecting the nasal passages (the primary point of entry for the virus), the vaccine has the potential to reduce reinfection.

Key Points: 
  • By protecting the nasal passages (the primary point of entry for the virus), the vaccine has the potential to reduce reinfection.
  • This study was designed to test the safety, immunogenicity and protection from infection and disease provided by ImmunityBios hAd5-COVID-19 vaccine.
  • ImmunityBios hAd5 vaccine activated T cells to provide protection, and N was particularly effective in this role.
  • ImmunityBios platform is based on the foundation of three separate modalities: antibody cytokine fusion proteins, synthetic immunomodulators, and second-generation human adenovirus (hAd5) vaccine technologies.

Evaxion Biotech Announces Publication in Nature Communications Describing Improved Selection of Immunotherapy Targets

Retrieved on: 
Wednesday, December 9, 2020
Immunology, Immunogenicity, Epitope, ImmunoGen

Evaxion has generated data on the thermostability of peptide-MHC complexes (pMHC), the biological context for antigen processing.

Key Points: 
  • Evaxion has generated data on the thermostability of peptide-MHC complexes (pMHC), the biological context for antigen processing.
  • The new data have already proved valuable in enabling Evaxions artificial neural networks to more readily predict the immunological behavior of the peptide epitopes.
  • By surveying the thermostability of thousands of pMHC interactions simultaneously by mass spectrometry, the Nature Communications paper provides an additional layer of previously unobtainable data on interactions within the pMHC.
  • That data enabled Evaxion to train its unique AI platform to select epitopes for optimal immunogenicity, which may lead to better patient-specific cancer immunotherapies.

European Commission approves MenQuadfi®, the latest innovation in meningococcal (MenACWY) vaccination for individuals 12 months of age and older

Retrieved on: 
Monday, November 23, 2020
Medical specialties, Clinical medicine, Medicine, Vaccination, Vaccines, Meningococcal vaccine, Sanofi, Vaccine, Meningococcal disease, Vaccination schedule, Immunogenicity, Neisseria meningitidis

The immunogenicity and safety of MenQuadfi were evaluated in over 6,300 healthy individuals aged 12 months and older, who received a single dose of MenQuadfi.1,2,3,4,5,6,7

Key Points: 
  • The immunogenicity and safety of MenQuadfi were evaluated in over 6,300 healthy individuals aged 12 months and older, who received a single dose of MenQuadfi.1,2,3,4,5,6,7
    MenQuadfi was compared with other licensed combination vaccines across all age groups.
  • Meningococcal disease is vaccine-preventable but, in spite of its threat, there is currently no common immunization schedule for it in Europe.
  • Following EC approval, MenQuadfi is expected to be available in several European countries from 2021 to help protect individuals 12 months of age and older.
  • With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

HOOKIPA Pharma Reports Third Quarter 2020 Financial Results and Provides a Corporate Update

Retrieved on: 
Thursday, November 12, 2020
Immunogenicity, Immunology

NEW YORK and VIENNA, Austria, Nov. 12, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, HOOKIPA), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reports its financial results for the third quarter ended September 30, 2020 and provides a corporate update.

Key Points: 
  • NEW YORK and VIENNA, Austria, Nov. 12, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, HOOKIPA), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reports its financial results for the third quarter ended September 30, 2020 and provides a corporate update.
  • In June 2020, HOOKIPA announced positive Phase 2 interim data on the trials primary endpoints: safety, and B cell and T cell immunogenicity.
  • HOOKIPA continues to accrue patients and plans to report preliminary efficacy and updated safety and immunogenicity data by the end of 2020.
  • A peer reviewed article in OncoImmunology issued in September 2020 recognized that HB-201 preclinical results demonstrated high immunogenicity.

Selecta Biosciences to Participate in Upcoming Investor Conferences

Retrieved on: 
Tuesday, November 10, 2020
Immunology, Immunogenicity, ImmunoGen

WATERTOWN, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selectas Chief Executive Officer, Carsten Brunn, Ph.D., will participate virtually in the following investor conferences in November:

Key Points: 
  • WATERTOWN, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selectas Chief Executive Officer, Carsten Brunn, Ph.D., will participate virtually in the following investor conferences in November:
    Selecta Biosciences Inc. (NASDAQ: SELB) is leveraging its clinically validated ImmTOR platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses.
  • With an observed ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the bodys natural self-tolerance in autoimmune diseases.
  • A wholly-owned program focused on addressing IgA nephropathy driven by ImmTOR and a therapeutic enzyme is also in development among additional product candidates.
  • Selecta recently licensed its Phase 3 clinical product candidate, SEL-212, in chronic refractory gout to Sobi.

Sensei Biotherapeutics Presents Additional Data from Phase 1/2 Clinical Trial of SNS-301 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Retrieved on: 
Monday, November 9, 2020
Oncology, Health, Infectious diseases, Hospitals, Clinical trials, Pharmaceutical, Biotechnology, Medical specialties, Clinical medicine, Medicine, Immunology, Clusters of differentiation, Immune system, Cancer immunotherapy, Immunotherapy, PD-L1, Immunogenicity, Immune tolerance, Society for Immunotherapy of Cancer, SNS-301, Sensei Biotherapeutics

The data were presented in a poster session at the Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting.

Key Points: 
  • The data were presented in a poster session at the Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting.
  • The multi-center Phase 1/2 clinical trial is designed to assess the safety, efficacy and immunogenicity of SNS-301 in SCCHN patients that did not achieve tumor reductions on anti-PD-1/PD-L1 therapy alone.
  • As of the data cutoff date of October 6, 2020, eleven patients were enrolled in the study and enrollment is ongoing.
  • SNS-301 is a first-in-class cancer immunotherapy designed to overcome immune tolerance and induce robust and durable antigen-specific humoral and cellular responses.

Arcellx Announces Clinical Data to be Presented at the 62nd American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Thursday, November 5, 2020
Life sciences, Immunology, Health sciences, Health care, Biotechnology, Pharmaceutical industry, Pharmacy, Specialty drugs, Immunogenicity, Autoimmunity, Biopharmaceutical, Trubion

Arcellxs proprietary binding domainsa central component of Arcellxs ARC-sparX platformare novel synthetic proteins engineered for reduced immunogenicity and designed to bind specific therapeutic targets.

Key Points: 
  • Arcellxs proprietary binding domainsa central component of Arcellxs ARC-sparX platformare novel synthetic proteins engineered for reduced immunogenicity and designed to bind specific therapeutic targets.
  • The Arcellx ddBCMA cell therapy has been granted Fast Track Designation and Orphan Drug Designation by the U.S. Food and Drug Administration.
  • Arcellx has developed a collection of sparX proteins with unique binding domains directed at a number of therapeutic targets.
  • Arcellx is a clinical-stage biopharmaceutical company developing adaptive and controllable cell therapies for the treatment of patients with cancer and autoimmune diseases.

Genocea Provides Third Quarter 2020 Corporate Update

Retrieved on: 
Thursday, October 29, 2020
Medical specialties, Medicine, Clinical medicine, Immunology, European Society for Medical Oncology, Immunogenicity, Society for Immunotherapy of Cancer, Oncology, ESMO, Cancer immunotherapy, SITC, Immunotherapy

Genocea presented clinical response and immunogenicity data on the first five patients from Part B of the ongoing GEN-009 Phase 1/2a trial at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.

Key Points: 
  • Genocea presented clinical response and immunogenicity data on the first five patients from Part B of the ongoing GEN-009 Phase 1/2a trial at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.
  • Genocea will report additional clinical and immunogenicity data from the remaining GEN-009 Part B patients during the 2020 virtual Society for Immunotherapy of Cancer (SITC) annual meeting from November 9-14.
  • Net loss: Net loss was $4.6 million for the quarter ended September 30, 2020, compared to $7.5 million for the same period in 2019.
  • These forward-looking statements speak only as of the date of this press release and Genocea assumes no duty to update forward-looking statements, except as may be required by law.

UK Vaccines Taskforce has Selected Oxford Immunotec as the Sole Supplier of T cell Testing for SARS-CoV-2 Specific Responses in New COVID Vaccine Trials

Retrieved on: 
Thursday, October 22, 2020
Medical specialties, Medicine, Vaccines, Health, Medical research, COVID-19 vaccine, Biotechnology, Vaccine, Vaccination, Immunogenicity, HPV vaccine

Consequently, the UK Vaccines Taskforce is including T cell analysis in COVID vaccine trials.

Key Points: 
  • Consequently, the UK Vaccines Taskforce is including T cell analysis in COVID vaccine trials.
  • Kate Bingham, Chair of the UK Governments Vaccines Taskforce said; "The UK Vaccines Taskforce is delighted to be partnering Oxford Immunotec, an experienced team who are responsible for running the Vaccines Taskforce T cell tests to assess the immunogenicity of COVID-19 vaccines.
  • These attributes are essential in later stage large-scale vaccine trials, and will facilitate longitudinal studies and comparisons between trials.
  • The UK Vaccines Task Force has been commissioned to ensure the swift and safe implementation of a COVID vaccination in the UK.